
CS-O-00482 ·
Clearsynth · Cat: CS-O-00482
Reach 3+ verified distributors
Manufacturer product page
clearsynth.com/product/CS-O-00482
Description
Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasomea barrelshaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.
![Pyrazine-2-carboxylic acid (1-[3-methyl-1-(2,9-dimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0.2.6]dec-4-yl)-butylcarbamoyl]-2-phenyl-ethyl)-amide](https://structures.clearsynth.com/CS-O-42129.png)


![Pyrazine-2-carboxylic acid [1-(1-hydroxy-3-methyl-butyl carbamoyl)-2-phenyl-ethyl]-amide](https://structures.clearsynth.com/CS-O-36966.png)
